A citation-based method for searching scientific literature

T Kinno, K Tsuta, K Shiraishi, T Mizukami, M Suzuki, A Yoshida, K Suzuki, H Asamura, K Furuta, T Kohno, R Kushima. Ann Oncol 2014
Times Cited: 90







List of co-cited articles
867 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
358
52

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y Yeap, Lynette M Sholl, Bruce E Johnson, Pasi A Jänne. Clin Cancer Res 2013
234
46

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paul K Paik, Maria E Arcila, Michael Fara, Camelia S Sima, Vincent A Miller, Mark G Kris, Marc Ladanyi, Gregory J Riely. J Clin Oncol 2011
457
45

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
481
33

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
32

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.
Anya M Litvak, Paul K Paik, Kaitlin M Woo, Camelia S Sima, Matthew D Hellmann, Maria E Arcila, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely. J Thorac Oncol 2014
82
30

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Liza C Villaruz, Mark A Socinski, Shira Abberbock, Lynne D Berry, Bruce E Johnson, David J Kwiatkowski, A John Iafrate, Marileila Varella-Garcia, Wilbur A Franklin, D Ross Camidge,[...]. Cancer 2015
77
31

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
David Planchard, Tae Min Kim, Julien Mazieres, Elisabeth Quoix, Gregory Riely, Fabrice Barlesi, Pierre-Jean Souquet, Egbert F Smit, Harry J M Groen, Ronan J Kelly,[...]. Lancet Oncol 2016
260
25

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
24

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
22

BRAF-mutations in non-small cell lung cancer.
Odd Terje Brustugun, Asma Malik Khattak, Anette Kjoshagen Trømborg, Marzieh Beigi, Klaus Beiske, Marius Lund-Iversen, Åslaug Helland. Lung Cancer 2014
48
41

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
21


Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Claire Tissot, Sébastien Couraud, Ronan Tanguy, Pierre-Paul Bringuier, Nicolas Girard, Pierre-Jean Souquet. Lung Cancer 2016
87
21

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
18

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
18

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
454
18

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
17

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
17

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
16

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
16

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Dong Chen, Li-Qun Zhang, Jun-Fu Huang, Kai Liu, Zheng-Ran Chuai, Zhao Yang, Yun-Xia Wang, Da-Chuan Shi, Qian Liu, Qing Huang,[...]. PLoS One 2014
64
23

Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Masashi Kobayashi, Makoto Sonobe, Tsuyoshi Takahashi, Akihiko Yoshizawa, Masashi Ishikawa, Ryutaro Kikuchi, Kenichi Okubo, Cheng-Long Huang, Hiroshi Date. Anticancer Res 2011
55
27

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
16

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
901
15

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
15

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
572
14

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Alexander Drilon, Lu Wang, Adnan Hasanovic, Yoshiyuki Suehara, Doron Lipson, Phil Stephens, Jeffrey Ross, Vincent Miller, Michelle Ginsberg, Maureen F Zakowski,[...]. Cancer Discov 2013
350
14

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
14

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
420
14


Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
M Ilie, E Long, V Hofman, B Dadone, C H Marquette, J Mouroux, J M Vignaud, H Begueret, J P Merlio, D Capper,[...]. Ann Oncol 2013
88
14

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle,[...]. J Thorac Oncol 2015
113
14

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
14

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
13

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Lecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun-Ming Tsai, Michael Boyer,[...]. J Clin Oncol 2013
13

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
13

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
13

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
13

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, Didier Debieuvre, Jean Mosser, Hervé Lena, L'Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel,[...]. Lancet 2016
557
13

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
616
12

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
12

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
12

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
12

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Solange Peters, Olivier Michielin, Stefan Zimmermann. J Clin Oncol 2013
76
14

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
351
12

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Marcin Imielinski, Alice H Berger, Peter S Hammerman, Bryan Hernandez, Trevor J Pugh, Eran Hodis, Jeonghee Cho, James Suh, Marzia Capelletti, Andrey Sivachenko,[...]. Cell 2012
12

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Oliver Gautschi, Chantal Pauli, Klaus Strobel, Astrid Hirschmann, Gert Printzen, Stefan Aebi, Joachim Diebold. J Thorac Oncol 2012
104
12

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
12

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Sara D Robinson, Joyce A O'Shaughnessy, C Lance Cowey, Kartik Konduri. Lung Cancer 2014
59
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.